VACCINE FORMULATION INSTITUTE(CH)LTD

Their core work

The Vaccine Formulation Institute (VFI) is a Swiss organization specializing in vaccine formulation, adjuvant development, and antigen design. They contribute formulation expertise to large European vaccine development consortia targeting diseases including HIV and malaria. Their work spans from antigen discovery and multi-antigen vaccine construction to supporting the design of pan-European vaccine R&D infrastructure.

What they specialise in

How they've shifted over time

VFI's early H2020 involvement (2016–2017) centered on disease-specific vaccine development — first HIV vaccines through EHVA, then malaria vaccines through OptiMalVax, both as a contributing partner. By 2020, their focus shifted toward the structural side of vaccine R&D with TRANSVAC-DS, a design study for European vaccine infrastructure. This progression suggests a move from project-level formulation work toward shaping the broader European vaccine development ecosystem.

VFI appears to be transitioning from disease-specific vaccine formulation toward a role in European vaccine infrastructure and platform development, which could position them as a go-to partner for new vaccine initiatives.

How they like to work

VFI operates exclusively as a participant, never as coordinator, across all three projects. They work within large consortia — 83 unique partners across 19 countries indicates involvement in major EU-wide platforms rather than small focused teams. This profile suggests a specialist contributor that brings targeted formulation expertise to large collaborative efforts rather than driving project direction.

VFI has collaborated with 83 unique partners across 19 countries through just 3 projects, reflecting their participation in large pan-European vaccine consortia. Their network spans a wide geographic range, typical of major health research alliances.

What sets them apart

VFI occupies a niche as a dedicated vaccine formulation organization based in Switzerland — not a university, not a pharma company, but a focused institute bridging the gap between antigen research and deployable vaccine products. Their combination of hands-on formulation experience (adjuvants, virus-like-particles, multi-antigen constructs) with involvement in infrastructure planning makes them a practical partner for consortia that need formulation expertise without the overhead of a large pharmaceutical entity.

Highlights from their portfolio

• OptiMalVax
  Targeted a deployable high-efficacy malaria vaccine using advanced multi-antigen and virus-like-particle technology — the most technically specific of VFI's projects.
• TRANSVAC-DS
  VFI's only directly funded project (EUR 28,750), focused on designing European vaccine infrastructure — signals their growing role in shaping the vaccine R&D landscape.
• EHVA
  A major 7-year EU platform for HIV vaccine discovery involving a large consortium, showing VFI's ability to contribute to long-running flagship initiatives.